Phase 1 Hyperactivity Clinical Trials

8 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)
Universidade do Sul de Santa Catarina60 enrolled1 locationNCT07592390
Recruiting
Phase 1

Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

Cognitive ImpairmentSickle Cell DiseaseAttention Deficit Hyperactivity Disorder (ADHD)+1 more
St. Jude Children's Research Hospital72 enrolled1 locationNCT07226219
Recruiting
Phase 1

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity DisorderBorderline Personality Disorder
Boehringer Ingelheim96 enrolled12 locationsNCT07001475
Recruiting
Phase 1Phase 2

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Attention Deficit Hyperactivity Disorder
National Institute of Mental Health (NIMH)219 enrolled1 locationNCT05608434
Recruiting
Phase 1

Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
The Second Hospital of Nanjing Medical University50 enrolled2 locationsNCT06376331
Not Yet Recruiting
Phase 1

Effects of mild brain stimulation in children with attention deficit hyperactivity disorder (ADHD)

Attention Deficit Hyperactivity Disorder
University of Newcastle20 enrolled1 locationACTRN12614001331628
Withdrawn
Phase 1

Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteers

Attention Deficit Hyperactivity Disorder (ADHA)
Impax Laboratories, Inc20 enrolled1 locationACTRN12614000518662
Completed
Phase 1

Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy Volunteers

Attention Deficit Hyperactivity Disorder (ADHD)
Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.20 enrolled1 locationACTRN12613001073796